Literature DB >> 19159118

On the origins of complex immune-mediated disease: the example of rheumatoid arthritis.

Lars Klareskog1, Sara Wedrén, Lars Alfredsson.   

Abstract

This essay discusses strategies for understanding the origins and outcomes of complex chronic inflammatory diseases using genetic and environmental determinants as tools for new definitions of disease subsets. Rheumatoid arthritis has been chosen as the prototype to illustrate these general concepts. Through recent data on two different disease subsets, it has been possible to devise a new molecular model for disease development by incorporating multiple genes and environmental agents which generate immune reactions that may eventually cause disease. These kinds of studies, aiming to integrate genetic epidemiology and molecular immunology, require close proximity between institutions for molecular medicine, clinical departments able to provide follow-up, careful surveillance of large patient groups and collaboration with experts in epidemiology and biostatistics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19159118     DOI: 10.1007/s00109-008-0437-9

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  40 in total

1.  The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; Tom W J Huizinga; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2006-04

Review 2.  The links between joint damage and disability in rheumatoid arthritis.

Authors:  D L Scott; K Pugner; K Kaarela; D V Doyle; A Woolf; J Holmes; K Hieke
Journal:  Rheumatology (Oxford)       Date:  2000-02       Impact factor: 7.580

3.  Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.

Authors:  Robert M Plenge; Leonid Padyukov; Elaine F Remmers; Shaun Purcell; Annette T Lee; Elizabeth W Karlson; Frederick Wolfe; Daniel L Kastner; Lars Alfredsson; David Altshuler; Peter K Gregersen; Lars Klareskog; John D Rioux
Journal:  Am J Hum Genet       Date:  2005-11-01       Impact factor: 11.025

4.  Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis.

Authors:  Kristine A Kuhn; Liudmila Kulik; Beren Tomooka; Kristin J Braschler; William P Arend; William H Robinson; V Michael Holers
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

5.  The K/BxN mouse model of inflammatory arthritis: theory and practice.

Authors:  Paul Monach; Kimie Hattori; Haochu Huang; Elzbieta Hyatt; Jody Morse; Linh Nguyen; Adriana Ortiz-Lopez; Hsin-Jung Wu; Diane Mathis; Christophe Benoist
Journal:  Methods Mol Med       Date:  2007

6.  Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule.

Authors:  Jonathan A Hill; Scott Southwood; Alessandro Sette; Anthony M Jevnikar; David A Bell; Ewa Cairns
Journal:  J Immunol       Date:  2003-07-15       Impact factor: 5.422

7.  A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis.

Authors:  Leonid Padyukov; Camilla Silva; Patrik Stolt; Lars Alfredsson; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2004-10

8.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.

Authors:  Ann B Begovich; Victoria E H Carlton; Lee A Honigberg; Steven J Schrodi; Anand P Chokkalingam; Heather C Alexander; Kristin G Ardlie; Qiqing Huang; Ashley M Smith; Jill M Spoerke; Marion T Conn; Monica Chang; Sheng-Yung P Chang; Randall K Saiki; Joseph J Catanese; Diane U Leong; Veronica E Garcia; Linda B McAllister; Douglas A Jeffery; Annette T Lee; Franak Batliwalla; Elaine Remmers; Lindsey A Criswell; Michael F Seldin; Daniel L Kastner; Christopher I Amos; John J Sninsky; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

Review 9.  Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis.

Authors:  R Holmdahl; J C Lorentzen; S Lu; P Olofsson; L Wester; J Holmberg; U Pettersson
Journal:  Immunol Rev       Date:  2001-12       Impact factor: 12.988

Review 10.  Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis.

Authors:  Walther J van Venrooij; Albert J W Zendman
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

View more
  5 in total

Review 1.  Anti-CCP antibodies: the past, the present and the future.

Authors:  Walther J van Venrooij; Joyce J B C van Beers; Ger J M Pruijn
Journal:  Nat Rev Rheumatol       Date:  2011-06-07       Impact factor: 20.543

2.  Causal graph-based analysis of genome-wide association data in rheumatoid arthritis.

Authors:  Alexander V Alekseyenko; Nikita I Lytkin; Jizhou Ai; Bo Ding; Leonid Padyukov; Constantin F Aliferis; Alexander Statnikov
Journal:  Biol Direct       Date:  2011-05-18       Impact factor: 4.540

3.  Genetic risk score predicting risk of rheumatoid arthritis phenotypes and age of symptom onset.

Authors:  Lori B Chibnik; Brendan T Keenan; Jing Cui; Katherine P Liao; Karen H Costenbader; Robert M Plenge; Elizabeth W Karlson
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

4.  Prevalence of anti-citrullinated protein antibodies (ACPA) in patients with diffuse large B-cell lymphoma (DLBCL): a case-control study.

Authors:  Gunter Assmann; Klara Shihadeh; Viola Poeschel; Niels Murawski; Jutta Conigliarou; Mei Fang Ong; Michael Pfreundschuh
Journal:  PLoS One       Date:  2014-02-07       Impact factor: 3.240

Review 5.  Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.

Authors:  Ennio G Favalli
Journal:  Rheumatol Ther       Date:  2020-07-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.